Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in Moderate to Severe Crohn's Disease
NCT01545050Phase 2Terminated
- Sponsor
- CSL Limited
- Start
- Jun 2012
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial of clazakizumab in Crohn's disease (9 arms), sponsored by CSL Limited. Primary endpoint: Percent of Participants With Clinical Remission (CDAI<150) at 8 weeks. Started Jun 2012; status: terminated.
02
Drugs
clazakizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01545050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01545050.